Gabapentinoids-Related Delirium Adverse Events: A Real-World Study from 2004 to 2022 Based on FAERS

Figures & data

Figure 1 The flowchart of AE records in the FAERS database.

Figure 2 The reporting rates of delirium linked to gabapentinoids were compared to those of several comparators in Model 1.

Figure 3 The reporting rates of delirium linked to gabapentinoids were compared to those of several comparators in Model 2.

Figure 4 The reporting rates of delirium linked to gabapentinoids were compared to those of several comparators in Model 3.

Figure 5 The reporting rates of delirium linked to gabapentinoids were compared to those of several comparators in Model 4.

Figure 6 Delirium ROR and PRR of gabapentin versus non-gabapentin were stratified by age.

Figure 7 Delirium ROR and PRR occurred at different age in patients taking gabapentinoids.

Note: a is the number of delirium AE records for ≥65; b is the number of other AE for ≥65; a’ is the number of delirium AE records for <65; b’ is the number of other AE for <65; a’ and b’ replace c and d of the original formula, respectively.

Figure 8 Delirium ROR and PRR occurred at different sex in patients taking gabapentinoids.

Note: a is the number of delirium AE records for ≥65; b is the number of other AE for ≥65; a’ is the number of delirium AE records for <65; b’ is the number of other AE for <65; a’ and b’ replace c and d of the original formula, respectively.

Data Sharing Statement

This study analyzed publicly available datasets. These data can be found in the following locations: 1) https://research.cchmc.org/aers/explore.jsp; 2) https://fis.fda.gov/sense /app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-D58b-4203-a8aa-6d3021737452/state/analysis.